An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

NCT06894511 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: AAA617
DRUG: ARPI: Abiraterone
DRUG: ARPI: Enzalutamide

Sponsor

Novartis Pharmaceuticals